Company intelligence / Profile preview
Turn Biotechnologies
Mountain View, California, United Statesturn.bio ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Turn Bio is advancing pre-clinical research for multiple indications including dermatology and immunology applications. Their lead candidate TRN-001 for skin rejuvenation uses the eTurna platform, while other candidates for ophthalmology and immune cell rejuvenation are being developed with the recently acquired ARMMs technology. The company hopes to advance to clinical trials in 2023 as mentioned in earlier reports[8].
- Therapeutic areas
- Metabolic DisordersImmunologyOtherDermatologyRheumatologyOphthalmology
- Modalities
- mRNA-based therapiesepigenetic reprogramming
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
HanAll BiopharmaAstellas Venture ManagementDaewoong Pharmaceuticals
Beyond the preview
Go deeper on Turn Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Turn Biotechnologies.